IARS, AUA & SOCCA 2023 ABSTRACT SUBMISSIONS

General abstract submission for the 2023 Annual Meetings is now closed. Notifications will be sent the first week of February 2023. IARS late-breaking abstract submission is open and will close February 3, 2023. 

Please note – you will not be able to view submitted abstracts in your account while they are in the review process. 

Revisions to the Abstract Submission, including the Author Listing, Title, Body and Figures, are not permitted once the submission deadline has passed. The Abstract will be included in the Annual Meeting materials exactly as submitted.

As noted during abstract submission, the author that was designated during the submission process as the Presenting Author will be the first author in the final author listing. Should you change the presenting author for the meeting, we are unable to change the author listing and it will be published as it was submitted.

IARS Late-Breaking Abstract Submission

Late-breaking abstract submission for the IARS meeting is now open. The late-breaking abstract category allows for the submission of truly late-breaking, high-impact scientific research for which results were not available at the time of the general abstract submission deadline.

Late-breaking abstracts should present data that are high impact, ground breaking, innovative, and newsworthy. Medically challenging cases are not accepted for late-breaking submission.

Submission Deadline: February 3, 2023

Submit a Late-Breaking Abstract

LATE-BREAKING SUBMISSION GUIDELINES

When preparing your abstracts, please review the complete Submission Guidelines.

IARS is the only meeting that accepts late-breaking submissions. Medically challenging cases are not accepted. Late-breaking abstract submissions will be considered for in person poster presentations only. Late-breaking abstracts are not eligible for abstract awards.

Revisions to the Abstract Submission, including the Author Listing, Title, Body and Figures, are not permitted once the submission deadline has passed. The Abstract will be included in the Annual Meeting materials exactly as submitted.

As noted during abstract submission, the author that was designated during the submission process as the Presenting Author will be the first author in the final author listing. Should you change the presenting author for the meeting, we are unable to change the author listing and it will be published as it was submitted.

Late-Breaking Submission Rules

• Revisions are not allowed after the submission deadline. The abstract will be listed in all program materials as submitted.
• There are no restrictions on the number of submissions per submitter.
• The abstract text must be in English.
• The Introduction, Methods, Results and Conclusions sections cannot exceed 4500 characters (including spaces) combined. Each section cannot exceed 2500 characters (including spaces).
• Brand Names are prohibited. Please use the generic name.
• Abstract reviews are blinded. Do not include the institution in the abstract body or title.
• Research presented at the 2023 Annual Meetings should not be published in an indexed journal prior to the 2023 Annual Meetings.

Human Subjects

• Human subjects should not be identifiable. Do not disclose patients’ names, initials, hospital numbers, dates of birth, or other protected health care information.
• Please review the WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/.
• Retain copies of the IRB approval and documentation of written informed consent from each study subject.
• Please review the US Department of Health & Human Services Guidelines: https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html#standard.

Animal Subjects

• Research performed in vertebrate animals must explicitly state that the study was approved by the authors’ IRB for animal research (e.g., the Institutional Animal Care and Use Committee).
• Please review the US Public Health Service Policy on Humane Care and Use of Laboratory Animals: https://olaw.nih.gov/policies-laws/phs-policy.htm.

Submission Best Practices

• Originality and Scientific Merit: Were novel concepts or approaches used? Does the abstract challenge existing paradigms or develop new methodologies or technologies? Does the abstract address an important problem? Was scientific knowledge advanced?
• Quality and Integrity of Research Design and Data Analysis: Is the study design clearly described? Are issues of reliability and validity of the measures addressed? Are the statistical analyses appropriate?
• Conclusions: Are conclusions clearly stated? How well are the conclusions justified by the data?
• Technical Writing: Is the abstract clearly written and well-organized, or is the abstract difficult to follow and unfocused? Are there virtually no spelling, punctuation, or grammatical errors, or do the errors pose a distraction to the content provided in the abstract submission?